reports
- Jean Danjou
- Oliver Metzger
- Thomas Zlowodzki
A1XEH4 CROSSJECT SA
TFI TELEVISION FRANCAISE 1 SA
ISS ISS A/S
NRG NRJ GROUP SA
ALTA ALTAREA SCA
BOSS HUGO BOSS AG
G24 SCOUT24 AG
BAMNB KONINKLIJKE BAM GROEP NV
GLB GLANBIA PLC
SAVE SAVENCIA SA
FIE FIELMANN AG
VID VIDRALA SA
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
AED AEDIFICA SA
BEZ BERENTZEN GRUPPE
WAF SILTRONIC AG
TWEKA TKH GROUP N.V. CERT
OREGE OREGE SA
LNSX SIXT LEASING AG
FFARM FORFARMERS
MVC METROVACESA SA
VOS VOSSLOH AG
NEOEN NEOEN S.A.
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
C3RY CHERRY AG
- Jean Danjou
- Oliver Metzger
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2024
Nous sortons GALP de notre liste ODDO BHF European Large Caps. La valeur a réalisé une performance de +31,3% depuis son entrée le 20 mars dernier. Notre analyste adopte ce jour une opinion Neutre (vs Surperformance) sur la valeur qui a atteint notre objectif de cours. - ...
A1XEH4 CROSSJECT SA
TFI TELEVISION FRANCAISE 1 SA
ISS ISS A/S
NRG NRJ GROUP SA
ALTA ALTAREA SCA
BOSS HUGO BOSS AG
G24 SCOUT24 AG
BAMNB KONINKLIJKE BAM GROEP NV
GLB GLANBIA PLC
SAVE SAVENCIA SA
FIE FIELMANN AG
VID VIDRALA SA
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
AED AEDIFICA SA
BEZ BERENTZEN GRUPPE
WAF SILTRONIC AG
TWEKA TKH GROUP N.V. CERT
OREGE OREGE SA
LNSX SIXT LEASING AG
FFARM FORFARMERS
MVC METROVACESA SA
VOS VOSSLOH AG
NEOEN NEOEN S.A.
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
C3RY CHERRY AG
- Jean Danjou
- Oliver Metzger
Fielmann AG : Activity a shade more dynamic than anticipated, guidance...
>Q1 sales reflect stronger growth than anticipated at +11% but margins remain around the same as the year-earlier level - At the same time as the full publication of annual results (with the key elements already communicated on 29 February) the group announced those related to Q1 2024. FY23 sales were confirmed at € 1,969m, i.e. growth of 12% and c.8% organic (Q4 sales at 7%, i.e. more or less flat on an organic basis with Germany at -3.5%), EBT came in a shade ab...
- Jean Danjou
- Oliver Metzger
Fielmann AG : Activité un peu plus dynamique qu’attendu, guidance en m...
>Le CA T1 reflète une croissance plus favorable que prévu à +11% mais les marges restent du même ordre de grandeur que l’an passé sur le trimestre - Le groupe publie en même temps les résultats annuels 2023 complets (les principales données avaient déjà été communiquées le 29 février) et ceux afférents au T1 2024. Le CA 2023 est confirmé à 1969 M€ soit une croissance de 12% et c.8% en organique (CA T4 à 7% soit quasi flat en org avec une Allemagne à -3.5%), l’EBT ...
- Jean Danjou
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 04/30/2024
BHP's bid for Anglo American has confirmed interest from miners in copper in the context of increasingly challenged production and difficulties in fully completing projects. Anglo’s (Neutral) prospects in copper are now better valued and this is also the case for BHP (Neutral vs Underperform) although not so for Rio Tinto (Outperform vs Neutral). Downstream, Nexans and Montana Aerospace are our Top Picks (Outperform) vs Aurubis, Rexel and Prysmian (Neutral). - ...
CRI CHARGEURS SA
VCT VICAT-CIMENTS VICAT SA
FLY SOCIETE FONCIERE LYONNAISE SA
TYRES NOKIAN RENKAAT OYJ
VETO VETOQUINOL SA
BAMNB KONINKLIJKE BAM GROEP NV
BIG BIGBEN INTERACTIVE SA
GMM GRAMMER AG
FIE FIELMANN AG
DEZ DEUTZ AG
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
ARCAD ARCADIS NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
ROYAL VOPAK NV
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
FTG111 FLATEXDEGIRO AG
UNI UNICAJA BANCO S.A.
MOR MORPHOSYS AG
NFN NFON AG
WAVE WAVESTONE SA
NACON NACON SASU
ALHRS HYDROGEN REFUELING SOLUTIONS
ANTIN ANTIN INFRASTRUCTURE PARTNERS
FPE3 FUCHS PETROLUB SE
EXN EXCLUSIVE NETWORKS SA
WAGA WAGA ENERGY SA
- Jean Danjou
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 30/04/2024 Date Performance dep...
L’offre de BHP sur Anglo American a confirmé l’intérêt des minières pour le cuivre dans un contexte de tensions croissantes sur la production et de difficultés à faire aboutir les projets. Les perspectives d’Anglo (Neutre) dans le cuivre sont désormais mieux valorisées, c’est aussi le cas de BHP (Neutre vs Sous-performance) mais pas encore assez, selon nous, sur Rio Tinto (Surperformance vs Neutre). En aval, Nexans et Montana Aerospace sont nos valeurs préférées (Surperformance) vs Au...
CRI CHARGEURS SA
VCT VICAT-CIMENTS VICAT SA
FLY SOCIETE FONCIERE LYONNAISE SA
TYRES NOKIAN RENKAAT OYJ
VETO VETOQUINOL SA
BAMNB KONINKLIJKE BAM GROEP NV
BIG BIGBEN INTERACTIVE SA
GMM GRAMMER AG
FIE FIELMANN AG
DEZ DEUTZ AG
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
ARCAD ARCADIS NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
ROYAL VOPAK NV
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
FTG111 FLATEXDEGIRO AG
UNI UNICAJA BANCO S.A.
MOR MORPHOSYS AG
NFN NFON AG
WAVE WAVESTONE SA
NACON NACON SASU
ALHRS HYDROGEN REFUELING SOLUTIONS
ANTIN ANTIN INFRASTRUCTURE PARTNERS
FPE3 FUCHS PETROLUB SE
EXN EXCLUSIVE NETWORKS SA
WAGA WAGA ENERGY SA
- Jean Danjou
- Oliver Metzger
Fielmann AG : Top-line trends rather supportive but the guidance on pr...
>FY 2023 results confirmed, Q1 sales growth quite supportive at +11% but Q1 EBT just in line, FY 2024 growth expected double digit with EBT margin to improve - As usual at this point in the year, Fielmann releases at the same time 1) the final and complete FY 2023 results (prelim figures are reconfirmed: revenues at € 1970m, EBITDA at € 410m a 20.8% margin, EBT at € 194m 9.8% margin), 2) the results for Q1 2024: sales at € 529m, up 11% EBITDA at € 117m (margin 22.1% f...
- Jean Danjou
- Oliver Metzger
Fielmann AG : Top-line trends rather supportive but the guidance on pr...
>FY 2023 results confirmed, Q1 sales growth quite supportive at +11% but Q1 EBT just in line, FY 2024 growth expected double digit with EBT margin to improve - As usual at this point in the year, Fielmann releases at the same time 1) the final and complete FY 2023 results (prelim figures are reconfirmed: revenues at € 1970m, EBITDA at € 410m a 20.8% margin, EBT at € 194m 9.8% margin), 2) the results for Q1 2024: sales at € 529m, up 11% EBITDA at € 117m (margin 22.1% f...
- Oliver Metzger
- Stephan Wulf
MorphoSys AG : Article in STAT News again raised concerns that the acq...
>Q1 results as a non-event - Sales in Q1 2024 totalled € 27.5m (+13%). Operating expenses rose from € 79.4m in Q1 2023 to as much as € 289.1m. This massive increase in expenses is mainly due to the likely impact of the accelerated vesting of certain share-based payment programmes and the recognition of remuneration-related provisions following the planned acquisition by Novartis. As a result, the operating loss in the first quarter of 2024 amounted to -€ 264m compared...
EQS-News: Fielmann Group with +12% sales growth in 2023 and +11% growt...
EQS-News: Fielmann Group AG / Key word(s): Annual Report/Quarterly / Interim Statement Fielmann Group with +12% sales growth in 2023 and +11% growth in Q1/2024 (news with additional features) 30.04.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement. Fielmann Group with +12% sales growth in 2023 and +11% growth in Q1/2024 Audited FY2023 reporting in line with preliminary numbers published in February +11% sales growth in Q1/2024 over last year despite hard Q1/2023 comparables FY2024 forecast envisages double-digit topline growth, ...
EQS-News: Fielmann-Gruppe mit +12 % Umsatzwachstum in 2023 und +11 % W...
EQS-News: Fielmann Group AG / Schlagwort(e): Jahresbericht/Quartals-/Zwischenmitteilung Fielmann-Gruppe mit +12 % Umsatzwachstum in 2023 und +11 % Wachstum in Q1/2024 (News mit Zusatzmaterial) 30.04.2024 / 07:29 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Fielmann-Gruppe mit +12 % Umsatzwachstum in 2023 und +11 % Wachstum in Q1/2024 Geprüfter Jahresabschluss entspricht den im Februar veröffentlichten vorläufigen Zahlen Umsatz in Q1/2024 wächst trotz starker Q1/2023-Vergleichsbasis +11 % über Vorjahr Prognose für Geschäftsjahr 202...
EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, April 29, 2024 MorphoSys AG Reports First Quarter 2024 Financial Results Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion Received all mandatory antitrust approvals for the proposed acquisition by Novartis...
EQS-News: MorphoSys AG veröffentlicht Finanzergebnisse für das erste Q...
EQS-News: MorphoSys AG / Schlagwort(e): Quartals-/Zwischenmitteilung MorphoSys AG veröffentlicht Finanzergebnisse für das erste Quartal 2024 29.04.2024 / 22:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung Planegg/München, 29. April 2024 MorphoSys AG veröffentlicht Finanzergebnisse für das erste Quartal 2024 Abschluss eines Business Combination Agreement zur Übernahme durch Novartis für 68,00 € pro Aktie in bar, was einem Eigenkapitalwert von insgesamt 2,7 Milliarden € entspricht Erteilung aller erforderlichen ...
EQS-News: MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Stud...
EQS-News: MorphoSys AG / Schlagwort(e): Konferenz MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Studie zu Pelabresib bei Myelofibrose in mündlichem Vortrag auf der ASCO-Jahrestagung 2024 24.04.2024 / 16:40 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung Planegg/München, Deutschland, 24. April 2024 MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Studie zu Pelabresib bei Myelofibrose in mündlichem Vortrag auf der ASCO-Jahrestagung 2024 Weitere Posterpräsentation im Rahmen von ASCO 2024 zeigt neue Er...
EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabres...
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat Morpho...
- Thomas J. Schiessle
Übernahmeangebot von Novartis befürwortet – closing in H1/24 – NDA für...
MOR-Führungsgremien empfehlen Annahme des Übernahmeangebots. Die vorgeschlagene Übernahme durch Novartis sei „im besten Interesse von Morphosys, unseren Aktionärinnen und Aktionären und von Krebspatientinnen und -patienten weltweit", so Morphosys-CEO Jean-Paul Kress am 11.04.24. Die Offerte erfordert eine Mindestannahmeschwelle von 65 %. Die Angebotsfrist soll am 13. 05.24 enden. Mit Erscheinen dieser Publikation stellen wir die Coverage der MorphoSys AG ein.
- Thomas J. Schiessle
Takeover offer from Novartis approved by MOR Board - closing in H1/24 ...
The proposed takeover by Novartis is "in the best interest of Morphosys, our shareholders and cancer patients worldwide", said Morphosys CEO Jean-Paul Kress on 11.04.24. The offer requires a minimum acceptance threshold of 65%. The offer period is scheduled to end on 13 May 2024. With the release of this publication we will discontinue our coverage of MorphoSys AG.
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend...
EQS-News: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis 11.04.2024 / 14:38 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, April 11, 2024 MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit f...
EQS-News: Vorstand und Aufsichtsrat von MorphoSys empfehlen Annahme de...
EQS-News: MorphoSys AG / Schlagwort(e): Fusionen & Übernahmen/Verkauf Vorstand und Aufsichtsrat von MorphoSys empfehlen Annahme des öffentlichen Übernahmeangebots durch Novartis 11.04.2024 / 14:38 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung Planegg/München, Deutschland, 11. April 2024 Vorstand und Aufsichtsrat von MorphoSys empfehlen Annahme des öffentlichen Übernahmeangebots durch Novartis Novartis bietet € 68,00 pro Aktie in bar, was einem Eigenkapitalwert von insgesamt € 2,7 Milliarden entspricht Aktion...
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acq...
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act 22.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, March 22, 2024 MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in conne...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.